Climb Bio, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CLYM Nasdaq 2834 climbbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Climb Bio, Inc.

Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates - Aug 6th, 2026 5:00 am
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year? - Jul 8th, 2026 7:40 am
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026 - Jun 11th, 2026 5:00 am
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development - Jun 5th, 2026 5:00 am
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026 - May 26th, 2026 5:00 am
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect - May 20th, 2026 11:02 pm
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress - May 14th, 2026 5:00 am
Climb Bio to Present at Upcoming Investor Conferences - May 12th, 2026 5:00 am
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates - May 7th, 2026 5:00 am
Climb Bio Spotlights Budoprutug CD19 Strategy, Sets Up 2026 Data Readouts in pMN, ITP and SLE - May 5th, 2026 1:27 pm
Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing - May 5th, 2026 11:05 am
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts - May 5th, 2026 5:00 am
Why Climb Bio (CLYM) is One of the Best Performing Small Cap Stocks So Far in 2026 - May 1st, 2026 2:17 am
Climb Bio (CLYM) Receives FDA Fast Track Designation for Budoprutug in Rare Kidney Disease - Apr 29th, 2026 11:00 am
Climb Bio, Inc. Announces $110.0 Million Private Placement - Apr 28th, 2026 5:00 am
FDA Fast Track and a BTIG Buy; Is Climb Bio (CLYM) a Must-Buy Small Cap Stock? - Apr 20th, 2026 8:48 am
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026 - Apr 8th, 2026 5:00 am
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy - Apr 7th, 2026 5:00 am
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - Apr 6th, 2026 11:00 am
Climb Bio Highlights Budoprutug and CLYM116 Milestones, Sets Up “Rich Data Year” in 2026 - Mar 14th, 2026 6:03 am